You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • S61 Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL)

Article info

Article menu

Download PDFPDF

Treatment choices in cystic fibrosis and bronchiectasis: what works and when
S61 Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL)
Free

Authors

Citation

Castellani C, Simmonds N, Colombo C, et al
S61 Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL)
Thorax 2021;76:A41.

Publication history

  • First published November 8, 2021.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.